Folgen
Erik Sjögren
Erik Sjögren
PhD Biopharmaceutics
Bestätigte E-Mail-Adresse bei farmaci.uu.se
Titel
Zitiert von
Zitiert von
Jahr
PBPK models for the prediction of in vivo performance of oral dosage forms.
D Kostewicz, Aarons, Bolger, Sjögren
Eur J Pharm Sci, 2013
330*2013
In vivo methods for drug absorption–Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient …
E Sjögren, B Abrahamsson, P Augustijns, D Becker, MB Bolger, ...
European Journal of Pharmaceutical Sciences 57, 99-151, 2014
2972014
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim
E Sjögren, J Westergren, I Grant, G Hanisch, L Lindfors, H Lennernäs, ...
European journal of pharmaceutical sciences 49 (4), 679-698, 2013
1372013
Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods
D Dahlgren, C Roos, E Sjögren, H Lennernäs
Journal of pharmaceutical sciences 104 (9), 2702-2726, 2015
1002015
In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models
E Sjögren, H Thorn, C Tannergren
Molecular pharmaceutics 13 (6), 1763-1778, 2016
862016
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary Report
T Heimbach, S Suarez-Sharp, M Kakhi, N Holmstock, A Olivares-Morales, ...
The AAPS Journal 21, 1-15, 2019
762019
Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences
J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ...
CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019
732019
Applications of clinically relevant dissolution testing: workshop summary report
S Suarez-Sharp, M Cohen, F Kesisoglou, A Abend, P Marroum, ...
The AAPS Journal 20, 1-14, 2018
642018
In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context
H Lennernas, A Lindahl, A Van Peer, C Ollier, T Flanagan, R Lionberger, ...
Molecular Pharmaceutics 14 (4), 1307-1314, 2017
622017
Regional intestinal permeability of three model drugs in human
D Dahlgren, C Roos, A Lundqvist, B Abrahamsson, C Tannergren, ...
Molecular pharmaceutics 13 (9), 3013-3021, 2016
602016
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim
E Sjogren, J Westergren, I Grant, G Hanisch, L Lindfors, H Lennernas, ...
European Journal of Pharmaceutical Sciences 49 (4), 679-698, 2013
602013
Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data
E Sjogren, D Dahlgren, C Roos, H Lennernas
Molecular pharmaceutics 12 (6), 2026-2039, 2015
552015
In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations
C Roos, D Dahlgren, S Berg, J Westergren, B Abrahamsson, ...
Molecular Pharmaceutics 14 (12), 4233-4242, 2017
522017
The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km …
E Sjögren, H Lennernäs, TB Andersson, J Gråsjö, U Bredberg
Drug metabolism and disposition 37 (1), 47-58, 2009
502009
Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: Cell viability and oncologic protein profile
IR Dubbelboer, N Pavlovic, F Heindryckx, E Sjögren, H Lennernäs
Cancers 11 (7), 1024, 2019
492019
Concomitant intake of alcohol may increase the absorption of poorly soluble drugs
JH Fagerberg, E Sjögren, CAS Bergström
European Journal of Pharmaceutical Sciences 67, 12-20, 2015
472015
In vitro release mechanisms of doxorubicin from a clinical bead drug-delivery system
E Ahnfelt, E Sjögren, P Hansson, H Lennernäs
Journal of Pharmaceutical Sciences 105 (11), 3387-3398, 2016
462016
The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs
D Dahlgren, C Roos, P Johansson, C Tannergren, A Lundqvist, ...
International journal of pharmaceutics 547 (1-2), 158-168, 2018
432018
Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems
IR Dubbelboer, E Lilienberg, E Ahnfelt, E Sjögren, N Axén, H Lennernäs
Therapeutic delivery 5 (4), 447-466, 2014
422014
Pulmonary absorption–estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis
J Eriksson, E Sjögren, H Thörn, K Rubin, P Bäckman, H Lennernäs
European Journal of Pharmaceutics and Biopharmaceutics 124, 1-12, 2018
392018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20